Matinas BioPharma Holdings Inc (FRA:6LJ0)
€ 2.69 0 (0%) Market Cap: 3.23 Mil Enterprise Value: -7.02 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 57/100

Q2 2019 Matinas BioPharma Holdings Inc Earnings Call Transcript

Aug 13, 2019 / 12:00PM GMT
Release Date Price: €29.13 (-4.77%)
Operator

Greetings and welcome to the Matinas BioPharma quarterly update conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Peter Vozzo of Westwicke, Investor Relations for Matinas BioPharma. Please go ahead, Peter.

Peter Vozzo
Westwicke Partners, LLC - MD

Thank you, Kevin. Good morning, everyone, and thank you for joining the Matinas BioPharma second quarter results conference call.

Earlier this morning, we issued a press release with our second quarter 2019 financial results along with business updates. The release is available on the Matinas BioPharma website under the Investors section.

Joining me on the call today are Jerry Jabbour, Chief Executive Officer; Dr. Terry Ferguson, Chief Medical Officer; Dr. Terri Matkovits, Chief Development Officer; and Dr. Raphael Mannino, Chief Scientific Officer; and Keith Kucinski, Chief Financial Officer.

At this time, I would like to remind our listeners that remarks made during this call may

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot